AX-2026-042833 · Survodutide · GGPeps lot GGPE-2512-Y2660

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	97.44	% area	≥ 96.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	2.56	% area	≤ 3.5	PASS
Largest single impurity	RP-HPLC — aspartimide (−18 Da)	1.20	% area	≤ 1.00	FAIL
Identity — theoretical monoisotopic mass	calculated from molecular formula	4764.5121	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	4764.5240	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+2.5	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	87.49	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	85.25	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	16.42	mg	15 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	13.998	mg	15 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	93.3	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.46	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	8.85	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.20	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.66	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.66	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	18.78	min	18.90 ± 0.50 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.24	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	46,483	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Ser2]-diastereomer	0.68	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 46,483, and skew follows the reported asymmetry factor of 1.24. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.20 % impurity against a 97.44 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Survodutide — main peak	18.78	4,735,886	97.44	—
2	aspartimide (−18 Da)	19.36	58,324	1.20	-18.011
3	des-γGlu linker (−129 Da)	17.89	46,173	0.95	-129.043
4	C18 diacid mono-ester	20.12	13,123	0.27	+14.016
5	[D-Ser2]-diastereomer	18.54	2,916	0.06	0.000
6	truncated (2-39)	17.51	2,430	0.05	-137.059
7	survodutide dimer	22.56	1,458	0.03	+4764.512
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4764.5121 Da, computed from C220H340N50O67. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4764.5240 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
7+	681.6519	681.6536	0.0017	7.9
6+	795.0926	795.0946	0.0020	59.8
5+	953.9097	953.9121	0.0024	100.0
4+	1192.1353	1192.1383	0.0030	56.5
3+	1589.1780	1589.1819	0.0039	8.9

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.46
Counter-ion (TFA)	ion chromatography	8.85
Residual solvent + inorganic residue	estimated	0.20
Total peptide content	by difference	87.49
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	97.46	97.44	divergence -0.20 pp vs batch median
Total impurities (% area)	1.63	2.56
Largest single impurity (% area)	2.54	1.20
Water (%)	not stated	3.46
Counter-ion (%)	not stated	8.85
Peptide content (%w/w)	91.7	87.49
Endotoxin (EU/mg)	0.72	0.66
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 29 d) → laboratory (courier, dry ice, 6 d) → assay.
Assay date: 26 Apr 2026
Submitted to the index: 14 May 2026
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

ms_confirm14 May 2026

A reference standard on the same sequence would upgrade this from a good mass to a traceable one. The distinction matters where a result is going to be cited rather than merely read.

quad_unit14 May 2026

Mass, retention and impurity profile all agree on this record. Three independent constraints pointing the same way is the strongest identity evidence the index publishes.

tbu_residual14 May 2026

No +56 Da satellite in the envelope, which is the residual-protection signature. Its absence is worth as much as the parent mass being right.

lot_traceability14 May 2026

Lot GGPE-2512-Y2660 on the vial matches the certificate that came with it. That is the check every buyer can do in ten seconds and most do not.

Section 7

Related records

Same batch — lot GGPE-2512-Y2660 n=14

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042831	GGPE-2512-Y2660	Janoshik	2026-Q2	97.68	3.56	—	Buyer-sourced	2	MARGINAL
AX-2026-042832	GGPE-2512-Y2660	Kestrel	2026-Q2	98.68	3.59	92.0	Laboratory-retained	3	FAIL
AX-2026-042834	GGPE-2512-Y2660	Janoshik	2026-Q2	97.65	3.87	88.9	Buyer-sourced	3	MARGINAL
AX-2026-042835	GGPE-2512-Y2660	Janoshik	2026-Q2	97.77	4.16	—	Buyer-sourced	2	MARGINAL
AX-2026-042836	GGPE-2512-Y2660	Janoshik	2026-Q2	97.60	2.83	—	Buyer-sourced	2	MARGINAL
AX-2026-042837	GGPE-2512-Y2660	Janoshik	2026-Q2	97.63	3.04	—	Buyer-sourced	2	MARGINAL
AX-2026-042838	GGPE-2512-Y2660	Janoshik	2026-Q2	97.69	3.50	—	Buyer-sourced	2	MARGINAL
AX-2026-042839	GGPE-2512-Y2660	Janoshik	2026-Q2	97.37	3.92	95.0	Buyer-sourced	2	MARGINAL
AX-2026-042840	GGPE-2512-Y2660	PeptideMeter	2026-Q2	97.67	3.80	101.8	Buyer-sourced	2	MARGINAL
AX-2026-042841	GGPE-2512-Y2660	Janoshik	2026-Q2	97.71	3.99	—	Buyer-sourced	2	MARGINAL
AX-2026-042842	GGPE-2512-Y2660	Janoshik	2026-Q2	97.63	4.13	—	Buyer-sourced	2	MARGINAL
AX-2026-042843	GGPE-2512-Y2660	Nordanalyt	2026-Q2	97.37	3.00	—	Buyer-sourced	2	MARGINAL
AX-2026-042844	GGPE-2512-Y2660	Janoshik	2026-Q2	98.41	4.02	—	Supplier-supplied	2	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Survodutide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041831	GSP	GSP-2603-E3156	Kestrel	2026-Q3	99.91	5.50	93.2	Buyer-sourced	0	PASS
AX-2026-042706	ERP	ERP-2605-E9865	PeptideMeter	2026-Q3	98.38	5.33	103.5	Buyer-sourced	0	PASS
AX-2026-041836	GSP	GSP-2603-E3156	Janoshik	2026-Q3	98.65	5.34	90.3	Buyer-sourced	0	PASS
AX-2026-041837	GSP	GSP-2603-E3156	Janoshik	2026-Q3	98.33	5.37	—	Buyer-sourced	0	PASS
AX-2026-041833	GSP	GSP-2603-E3156	Janoshik	2026-Q3	98.08	4.91	99.3	Buyer-sourced	0	PASS
AX-2026-041832	GSP	GSP-2603-E3156	VendorInvestigate	2026-Q3	98.01	5.14	99.5	Buyer-sourced	0	PASS
AX-2026-041835	GSP	GSP-2603-E3156	Nordanalyt	2026-Q3	98.34	5.74	89.0	Buyer-sourced	1	MARGINAL
AX-2026-041834	GSP	GSP-2603-E3156	VendorInvestigate	2026-Q3	97.92	5.95	—	Buyer-sourced	0	PASS

Other recent GGPeps records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042784	CJC-1295 (no DAC)	GGPE-2606-E1234	Medutest	2026-Q3	98.27	4.55	—	Buyer-sourced	PASS
AX-2026-042786	CJC-1295 (no DAC)	GGPE-2606-E1234	Janoshik	2026-Q3	98.22	3.77	—	Buyer-sourced	PASS
AX-2026-042858	Selank	GGPE-2603-J2447	VendorInvestigate	2026-Q3	98.87	8.85	99.4	Buyer-sourced	FAIL
AX-2026-042783	CJC-1295 (no DAC)	GGPE-2606-E1234	Janoshik	2026-Q3	98.22	4.45	90.6	Buyer-sourced	PASS
AX-2026-042757	Melanotan II	GGPE-2603-P1474	Janoshik	2026-Q3	99.54	6.78	92.0	Buyer-sourced	PASS
AX-2026-042785	CJC-1295 (no DAC)	GGPE-2606-E1234	PeptideMeter	2026-Q3	97.70	4.64	91.4	Buyer-sourced	FAIL
AX-2026-042756	Melanotan II	GGPE-2603-P1474	Nordanalyt	2026-Q3	99.17	7.04	—	Buyer-sourced	PASS
AX-2026-042755	Melanotan II	GGPE-2603-P1474	Nordanalyt	2026-Q3	99.25	6.58	90.4	Buyer-sourced	PASS